Trials 84 · started per year
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 29 trials | ||||||
| Phase 2 | NCT03402464 Background | Jan 2018 → Jun 2019 | lung adenocarcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03123484 Background | Apr 2017 → Apr 2019 | non-small cell lung carcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03595644 Background | Feb 2017 → Jun 2019 | non-small cell lung carcinoma | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02788058 Background | May 2016 → May 2021 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02787447 Background | May 2016 → Dec 2017 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT03151161 Comparator | Dec 2015 → Dec 2018 | lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02027090 Comparator | Jan 2014 → Jun 2016 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01744925 Comparator | Oct 2012 → Nov 2017 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01690390 Comparator | Sep 2012 → Dec 2015 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04206072 Comparator | Dec 2019 → Jul 2022 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06041776 Comparator | Mar 2023 → Apr 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02882984 Background | Mar 2015 → Mar 2020 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02889692 Background | Mar 2013 → Dec 2016 | cancer | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| Phase 4 | NCT02103257 Comparator | Mar 2014 → Mar 2016 | adenocarcinoma, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04007835 Background | Jul 2019 → Jul 2021 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icotinib | “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗97“Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid” NCT03595644 ↗ “Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.” NCT04007835 ↗ “Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.” PMID 26148750 ↗ Jul 2015 “apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po” NCT03634059 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02788058 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02787447 ↗ “Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid” NCT02714010 ↗ “The MRD positive group would receive icotinib as adjuvant treatment.” NCT05536505 ↗ “Icotinib: 125 mg is administered orally three times per day.” NCT01707329 ↗ “Icotinib: 125mg, oral administration, three times per day.” NCT01665417 ↗ “EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7” NCT03008109 ↗ “icotinib will be administered 150mg/d ivgtt tid” NCT03258671 ↗ |
| Known as | Bpi-2009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2087361 ↗ |
| Known as | BPI-2009H | “Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.” PMID 22112293 ↗ Nov 2011 |
| Known as | Conmana | “The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung...” NCT01690390 ↗3“Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).” NCT02738983 ↗ “high dose of Icotinib (Conmana)” NCT01720901 ↗ |
| Known as | ectinib | “Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally” NCT03992885 ↗ |
| Known as | icotinib hydrochloride | “Icotinib Hydrochloride is an oral, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for treating advanced non-small...” NCT03222622 ↗3“To determine the pharmacokinetic (PK) profiles of icotinib (icotinib hydrochloride) in patients with advanced cancers.” NCT02033148 ↗ “Icotinib Hydrochloride is a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor” NCT02574091 ↗ |
| Action | Inhibit | “Icotinib, one of the leading compounds selected from our compound library, was found to be a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)” PMID 22112293 ↗ Nov 2011 |
| Modality | Small molecule | “Icotinib hydrochloride is a novel oral EGFR TKIs” NCT01534585 ↗ |
| Route | Oral | “Icotinib was administered at 125 mg orally 3 times/day until tumor progression or unacceptable toxicity” PMID 26148750 ↗ Jul 2015 |
| Target | EGFR | “Icotinib, one of the leading compounds selected from our compound library, was found to be a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)” PMID 22112293 ↗ Nov 2011 |